<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380976</url>
  </required_header>
  <id_info>
    <org_study_id>DW340-1002</org_study_id>
    <nct_id>NCT02380976</nct_id>
  </id_info>
  <brief_title>Phase 1 Clinical Trial of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dose, crossover Phase I Study to investigate the relative
      bioavailability of DW340 and DW330SR + DW1030 co-administration in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of DW330SR</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of DW340</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of DW1030</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of DW330SR</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of DW340</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of DW1030</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First phase: DW330SR+DW1030 7 days after Second phase: DW340</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First phase: DW340 7 days after Second phase: DW330SR+DW1030</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination drug: DW330SR, DW1030</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW340</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at screening visit only 20 healthy men over the age of 40 years or less

          -  Screening visit, BMI measurement is more than 19 kg/m2 who are below 27 kg/m2

          -  Screening vist, 90 mmHg ≤ SBP ≤ 140 mmHg, 50 mmHg ≤ DBP ≤ 90 mmHg

          -  Fully understand the purpose of trial, test drug and follow the instructions of the
             trial, Those who voluntarily written consent that ability and decision to participate
             during the entire period of the test

        Exclusion Criteria:

          -  Those with a clinically significant history or character; Liver, kidney, digestive,
             respiratory, musculoskeletal, endocrine, neuropsychiatric, blood • tumor type,
             cardiovascular disease

          -  Those with Gastrointestinal diseases that may affect the absorption of the IND or
             history of surgery

          -  Those who have a clinically significant history of hypersensitivity to drug and food

          -  Those with genetic problems, such as galactose intolerance, lactase deficiency or
             glucose-galactose malabsorption

          -  Within 60 days those taking the other clinical trial drug

          -  Within 30 days those who take the drug metabolizing enzyme induction and inhibition
             drugs or prescription drugs

          -  Within 30 days those who take food abnormally, that may affect ADME of drug

          -  Within 60 days those who donate whole blood, within 30 days those who donate blood
             partially, receive transfusion

          -  Within 14 days those who take OTC drug

          -  Those who showing positive for drug abuse concerns in urine drug testing

          -  Those who drink excessive alcohol or have history of alcoholism

          -  Heavy smoker

          -  and so on
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

